

22 December 2016

EFPIA Japan

Ole Mølskov Bech to become new chairman of EFPIA Japan

TOKYO—22 December 2016— EFPIA Japan announced today that Ole Mølskov Bech (President and Representative Director, Novo Nordisk Japan Ltd.) has been appointed the new chairman of EFPIA Japan, effective 1 January 2017.

Philippe Fauchet (President and Representative Director, GlaxoSmithKline K.K.), who continues in his current position as vice chairman, and David Fredrickson (President and Representative Director, AstraZeneca K.K.), who has been newly appointed vice chairman, will support Ole Mølskov Bech in his new role.

“EFPIA Japan has been focused during the past couple of years on ensuring patient access to innovative medicines in a sustainable Japanese healthcare system”, said Ole Mølskov Bech. “These objectives become even more of an imperative given the questions being raised about the pricing and access system today in Japan. As chairman of EFPIA Japan, I hope to be able to partner with key stakeholders in Japan for transparent and real dialogue and to ensure that EFPIA Japan is ready to contribute constructive propositions to the discussion.”

EFPIA Japan Board Members as of 1 January 2017

Chairman	Ole Mølskov Bech (Novo Nordisk Pharma Ltd.)	New
Vice Chairmen	Philippe Fauchet (GlaxoSmithKline K.K.)	
	David Fredrickson (AstraZeneca K.K.)	New
Directors	Dirk Kosche (Novartis Pharma K.K.)	
	Thorsten Poehl (Nippon Boehringer Ingelheim Co., Ltd.)	
	Jacques Nathan (Sanofi K.K.)	
	Heike Prinz (Bayer Yakuhin, Ltd.)	New
	Leo Lee (Merck Serono Co., Ltd.)	
	Stefan Sakurai (LEO Pharma K.K.)	
Director General	Simon Collier (EFPIA Japan)	

###

About EFPIA Japan:

Established in 2002, EFPIA Japan represents 24 R&D-based European pharmaceutical companies operating in Japan. In 2015, combined sales from the member companies accounted for roughly 24% of the pharmaceutical market in Japan. The mission of EFPIA Japan is to “Contribute to healthcare and patients in Japan through the early introduction of innovative medicines and vaccines”. EFPIA Japan aims to strengthen dialogue with decision-makers in order to improve Japanese healthcare for all.

About EFPIA (European Federation of Pharmaceutical Industries and Associations):

EFPIA, EFPIA Japan’s partner organisation, is headquartered in Brussels and represents the pharmaceutical industry operating in Europe. Through its direct membership of 33 national associations and 42 leading pharmaceutical companies, EFPIA provides the voice of 1,900 companies committed to researching, developing and bringing new medicines to improve health and quality of life around the world.

For more information please visit:

<http://www.efpia.eu> (EFPIA)

<http://efpia.jp/English/index-e.html> (EFPIA Japan)

Contact:

Naoko Miyoshi, Chair of EFPIA Japan Public Relations Committee

Bayer Yakuhin, Ltd.

TEL: 06-6133-7333

Mail: naoko.miyoshi@bayer.com

Dr. Ole Mølskov Bech's Curriculum Vitae



Birth Place Denmark

Birth Year 1959

Current Position

President and Representative Director, Novo Nordisk Pharma Ltd.

Education

1986 Medical Degree, University of Copenhagen

2002 MBA from Scandinavian International Management Institute

Work Experience

1986-1990 *Research Fellow*, Institute of Pharmacology, University of Aarhus and Clinical Training at Gentofte County Hospital

Dec 1990 Joined Novo Nordisk A/S as *International Product Manager* and based in Denmark

Jun 1992 *Regional Manager*, International Operations, Region V

Feb 1995 *Director and Executive Assistant for COO*

April 1997 *Director*, Marketing Support, International Operations Marketing

Dec 1998 *Vice President*, Customer Service and Shipping

Sep 2000 *Vice President*, Product Supply Operations

Aug 2001 *Vice President*, DAWN Project, Operations

Oct 2002 *Medical, Marketing and Business Development Director*
Regional Office Far East, International Operations – Based in Singapore

Nov 2003 *Medical Director*, International Operations Clinical Development Centre
Responsible for clinical development activities in Asia,
Latin America, Africa, Middle East, Eastern Europe and Russia – Based in Singapore

Feb 2006 *Vice President*, International Operations Clinical Development Centre,
Based in Beijing, China
Member of IO Management and Global Development Management

Jan 2011 *Corporate Vice President*, International Operations Clinical, Medical &
Regulatory – Based in Zurich, Switzerland

(As of December, 2016)

Member of IO Management and Global Development Management

Aug 2012 *Corporate Vice President, Business Area Near East, International Operations – Based in Istanbul, Turkey*
Responsible for business activities in 11 countries in the Near East
Member of IO Management

Jan 2016 *Senior Vice President, Region Japan & Korea, International Operations, President and Representative Director of Novo Nordisk Pharma Ltd.*
Responsible for business activities in Japan and Korea– Based in Tokyo, Japan
Member of Novo Nordisk Management Board

External Activities

2003-2006 *Committee Member, Danish Business Association of Singapore, Singapore*

2006-2012 *Board Member, Danish Chamber of Commerce in China, Beijing, China*

2007-2011 *Board of Trustee, International School of Beijing, Beijing, China*

Jul 2016 *Vice Chairman, European Federation of Pharmaceutical Industries (EFPIA Japan)*

Jan 2017 *Chairman, European Federation of Pharmaceutical Industries (EFPIA Japan)*

Others

Dr. Bech has published more than 30 papers and abstracts and has held lectures in Europe, Asia, the Middle East and Latin America.